BIO vs. ILMN, WAT, BIO.B, RVTY, TXG, OLK, AVTR, ELAN, GMED, and CHE
Should you be buying Bio-Rad Laboratories stock or one of its competitors? The main competitors of Bio-Rad Laboratories include Illumina (ILMN), Waters (WAT), Bio-Rad Laboratories (BIO.B), Revvity (RVTY), 10x Genomics (TXG), Olink Holding AB (publ) (OLK), Avantor (AVTR), Elanco Animal Health (ELAN), Globus Medical (GMED), and Chemed (CHE). These companies are all part of the "medical" sector.
Bio-Rad Laboratories (NYSE:BIO) and Illumina (NASDAQ:ILMN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, community ranking, media sentiment and analyst recommendations.
Illumina received 717 more outperform votes than Bio-Rad Laboratories when rated by MarketBeat users. Likewise, 65.71% of users gave Illumina an outperform vote while only 64.87% of users gave Bio-Rad Laboratories an outperform vote.
In the previous week, Illumina had 6 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 16 mentions for Illumina and 10 mentions for Bio-Rad Laboratories. Illumina's average media sentiment score of 0.51 beat Bio-Rad Laboratories' score of 0.36 indicating that Illumina is being referred to more favorably in the news media.
Bio-Rad Laboratories has higher earnings, but lower revenue than Illumina. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.
Bio-Rad Laboratories currently has a consensus target price of $461.00, suggesting a potential upside of 53.17%. Illumina has a consensus target price of $164.65, suggesting a potential upside of 43.16%. Given Bio-Rad Laboratories' stronger consensus rating and higher possible upside, equities analysts clearly believe Bio-Rad Laboratories is more favorable than Illumina.
Bio-Rad Laboratories has a net margin of -12.37% compared to Illumina's net margin of -28.71%. Bio-Rad Laboratories' return on equity of 3.59% beat Illumina's return on equity.
65.2% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 89.4% of Illumina shares are owned by institutional investors. 17.5% of Bio-Rad Laboratories shares are owned by company insiders. Comparatively, 0.2% of Illumina shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Bio-Rad Laboratories has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, Illumina has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500.
Summary
Illumina beats Bio-Rad Laboratories on 11 of the 18 factors compared between the two stocks.
Get Bio-Rad Laboratories News Delivered to You Automatically
Sign up to receive the latest news and ratings for BIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bio-Rad Laboratories Competitors List
Related Companies and Tools
